Search

Your search keyword '"Arredouani, Mohamed"' showing total 167 results
Start Over Author "Arredouani, Mohamed"
167 results on '"Arredouani, Mohamed"'

3. Supplementary Data from Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer

Author

Arredouani, Mohamed S., primary, Lu, Bin, primary, Bhasin, Manoj, primary, Eljanne, Miriam, primary, Yue, Wen, primary, Mosquera, Juan-Miguel, primary, Bubley, Glenn J., primary, Li, Vivian, primary, Rubin, Mark A., primary, Libermann, Towia A., primary, and Sanda, Martin G., primary

Published
2023
Full Text
View/download PDF

6. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function

Author

Ruggiero, Eliana, primary, Carnevale, Erica, additional, Prodeus, Aaron, additional, Magnani, Zulma Irene, additional, Camisa, Barbara, additional, Merelli, Ivan, additional, Politano, Claudia, additional, Stasi, Lorena, additional, Potenza, Alessia, additional, Cianciotti, Beatrice Claudia, additional, Manfredi, Francesco, additional, Di Bono, Mattia, additional, Vago, Luca, additional, Tassara, Michela, additional, Mastaglio, Sara, additional, Ponzoni, Maurilio, additional, Sanvito, Francesca, additional, Liu, Dai, additional, Balwani, Ishina, additional, Galli, Rossella, additional, Genua, Marco, additional, Ostuni, Renato, additional, Doglio, Matteo, additional, O’Connell, Daniel, additional, Dutta, Ivy, additional, Yazinski, Stephanie Ann, additional, McKee, Mark, additional, Arredouani, Mohamed Simo, additional, Schultes, Birgit, additional, Ciceri, Fabio, additional, and Bonini, Chiara, additional

Published
2022
Full Text
View/download PDF

9. Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/II

Author

Dahl, Morten, Bauer, Alison K., Arredouani, Mohamed, Soininen, Raija, Tryggvason, Karl, Kleeberger, Steven R., and Kobzik, Lester

Subjects
Lipids -- Research, Collagen diseases -- Care and treatment, Connective tissue cells -- Health aspects, Connective tissue cells -- Research, Macrophages -- Research, Oxidizing agents -- Health aspects, Oxidizing agents -- Research
Abstract

Alveolar macrophages (AMs) express the class A scavenger receptors (SRAs) macrophage receptor with collagenous structure (MARCO) and scavenger receptor AI/II (SRA-I/II), which recognize oxidized lipids and provide innate defense against [...]

Published
2007

15. Maternal allergic contact dermatitis causes increased asthma risk in offspring

Author

Kobzik Lester, Fedulov Alexey, Arredouani Mohamed S, Lim Robert H, and Hubeau Cedric

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Abstract Background Offspring of asthmatic mothers have increased risk of developing asthma, based on human epidemiologic data and experimental animal models. The objective of this study was to determine whether maternal allergy at non-pulmonary sites can increase asthma risk in offspring. Methods BALB/c female mice received 2 topical applications of vehicle, dinitrochlorobenzene, or toluene diisocyanate before mating with untreated males. Dinitrochlorobenzene is a skin-sensitizer only and known to induce a Th1 response, while toluene diisocyanate is both a skin and respiratory sensitizer that causes a Th2 response. Both cause allergic contact dermatitis. Offspring underwent an intentionally suboptimal protocol of allergen sensitization and aerosol challenge, followed by evaluation of airway hyperresponsiveness, allergic airway inflammation, and cytokine production. Mothers were tested for allergic airway disease, evidence of dermatitis, cellularity of the draining lymph nodes, and systemic cytokine levels. The role of interleukin-4 was also explored using interleukin-4 deficient mice. Results Offspring of toluene diisocyanate but not dinitrochlorobenzene-treated mothers developed an asthmatic phenotype following allergen sensitization and challenge, seen as increased Penh values, airway inflammation, bronchoalveolar lavage total cell counts and eosinophilia, and Th2 cytokine imbalance in the lung. Toluene diisocyanate treated interleukin-4 deficient mothers were able to transfer asthma risk to offspring. Mothers in both experimental groups developed allergic contact dermatitis, but not allergic airway disease. Conclusion Maternal non-respiratory allergy (Th2-skewed dermatitis caused by toluene diisocyanate) can result in the maternal transmission of asthma risk in mice.

Published
2007
Full Text
View/download PDF

18. Additional file 3: of An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

Author

Hill, Katherine, Kelly, Andrew, Kuijjer, Marieke, Barry, William, Rattani, Ahmed, Garbutt, Cassandra, Kissick, Haydn, Janeway, Katherine, Perez-Atayde, Antonio, Goldsmith, Jeffrey, Gebhardt, Mark, Arredouani, Mohamed, Cote, Greg, Hornicek, Francis, Choy, Edwin, Zhenfeng Duan, Quackenbush, John, Haibe-Kains, Benjamin, and Spentzos, Dimitrios

Abstract

Differentially expressed miRNAs between the two subtypes in the three datasets. The Boston, Utah, and cell line data were analyzed to determine the differential expression of their miRNA population. (PDF 154 kb)

Published
2017
Full Text
View/download PDF

19. Additional file 7: of An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

Author

Hill, Katherine, Kelly, Andrew, Kuijjer, Marieke, Barry, William, Rattani, Ahmed, Garbutt, Cassandra, Kissick, Haydn, Janeway, Katherine, Perez-Atayde, Antonio, Goldsmith, Jeffrey, Gebhardt, Mark, Arredouani, Mohamed, Cote, Greg, Hornicek, Francis, Choy, Edwin, Zhenfeng Duan, Quackenbush, John, Haibe-Kains, Benjamin, and Spentzos, Dimitrios

Abstract

Association between prognostic 14q32 miRNAs and cell line aggressiveness (binary analysis). An analysis between 14q32 miRNA expression and the following characteristics associated with cell line aggressiveness was performed: proliferation, invasiveness, migration, colony forming, and tumorigenicity. These attributes were analyzed as binary (categorical) variables. (PDF 538 kb)

Published
2017
Full Text
View/download PDF

20. Additional file 9: of An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

Author

Hill, Katherine, Kelly, Andrew, Kuijjer, Marieke, Barry, William, Rattani, Ahmed, Garbutt, Cassandra, Kissick, Haydn, Janeway, Katherine, Perez-Atayde, Antonio, Goldsmith, Jeffrey, Gebhardt, Mark, Arredouani, Mohamed, Cote, Greg, Hornicek, Francis, Choy, Edwin, Zhenfeng Duan, Quackenbush, John, Haibe-Kains, Benjamin, and Spentzos, Dimitrios

Abstract

Association between DLK1/MEG3 methylation and cell line aggressiveness. The relationship between methylation and cell line aggressiveness was analyzed for methylation site neighboring or on DLK1 and MEG3, both located on 14q32. This analysis was limited by the number of available methylation probes for this region on the Illumina methylation array. Cell line aggressiveness was assessed via colony forming, invasiveness, migration, and tumorigenicity. (PDF 447 kb)

Published
2017
Full Text
View/download PDF

21. Additional file 1: of An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

Author

Hill, Katherine, Kelly, Andrew, Kuijjer, Marieke, Barry, William, Rattani, Ahmed, Garbutt, Cassandra, Kissick, Haydn, Janeway, Katherine, Perez-Atayde, Antonio, Goldsmith, Jeffrey, Gebhardt, Mark, Arredouani, Mohamed, Cote, Greg, Hornicek, Francis, Choy, Edwin, Zhenfeng Duan, Quackenbush, John, Haibe-Kains, Benjamin, and Spentzos, Dimitrios

Abstract

Clinical characteristics of the Boston, Utah, and Texas datasets. These published datasets were used to assess the prognostic value of a subset of miRNA subsets located on 14q32 via the tdROC curve method. Available follow-up was different between the two datasets such that we needed to choose a primary endpoint of 120Â months for the Boston dataset and 60Â months for the Utah and Texas datasets. (PDF 141 kb)

Published
2017
Full Text
View/download PDF

22. Additional file 4: of An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

Author

Hill, Katherine, Kelly, Andrew, Kuijjer, Marieke, Barry, William, Rattani, Ahmed, Garbutt, Cassandra, Kissick, Haydn, Janeway, Katherine, Perez-Atayde, Antonio, Goldsmith, Jeffrey, Gebhardt, Mark, Arredouani, Mohamed, Cote, Greg, Hornicek, Francis, Choy, Edwin, Zhenfeng Duan, Quackenbush, John, Haibe-Kains, Benjamin, and Spentzos, Dimitrios

Subjects
fungi
Abstract

Correlations between DICER and differentially expressed miRNAs in the Boston dataset. DICER1 is a gene that encodes for an endoribonuclease essential for the formation of microRNA, and it is also located on 14q32. We analyzed the correlation between miRNA expression on the 14q32 locus and DICER1 expression and found that a small fraction (5%) of miRNAs was significantly correlated with DICER1. (PDF 174 kb)

Published
2017
Full Text
View/download PDF

23. Additional file 6: of An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

Author

Hill, Katherine, Kelly, Andrew, Kuijjer, Marieke, Barry, William, Rattani, Ahmed, Garbutt, Cassandra, Kissick, Haydn, Janeway, Katherine, Perez-Atayde, Antonio, Goldsmith, Jeffrey, Gebhardt, Mark, Arredouani, Mohamed, Cote, Greg, Hornicek, Francis, Choy, Edwin, Zhenfeng Duan, Quackenbush, John, Haibe-Kains, Benjamin, and Spentzos, Dimitrios

Abstract

Correlations between prognostic miRNAs and other 14q32 transcripts in the Boston dataset. Eighteen prognostic miRNAs that we found on 14q32 were compared with the remaining coding and non-coding transcripts on that same locus to investigate whether a larger pattern of co-regulation may exist. (PDF 424 kb)

Published
2017
Full Text
View/download PDF

24. A safety-modified SV40 Tag developed for human cancer immunotherapy

Author

Tseng-Rogenski, Stephanie S, Arredouani, Mohamed S, Escara-Wilke, June F, Neeley, Yilin C, Imperiale, Michael J, and Sanda, Martin G

Subjects
cancer immunotherapy, modified SV-40 T antigen, recombinant vaccinia, Original Research
Abstract

Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag to transform cells and to interact with anti-oncoproteins, as well as screened for the presence of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes within mTag sequence were identified. Our results show that mTag lacks the oncogenicity of full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence suggesting the safety of vac-mTag for use in cancer immunotherapy.

Published
2009

26. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

Author

Hill, Katherine E., primary, Kelly, Andrew D., additional, Kuijjer, Marieke L., additional, Barry, William, additional, Rattani, Ahmed, additional, Garbutt, Cassandra C., additional, Kissick, Haydn, additional, Janeway, Katherine, additional, Perez-Atayde, Antonio, additional, Goldsmith, Jeffrey, additional, Gebhardt, Mark C., additional, Arredouani, Mohamed S., additional, Cote, Greg, additional, Hornicek, Francis, additional, Choy, Edwin, additional, Duan, Zhenfeng, additional, Quackenbush, John, additional, Haibe-Kains, Benjamin, additional, and Spentzos, Dimitrios, additional

Published
2017
Full Text
View/download PDF

29. The immune boundaries for stem cell based therapies: Problems and prospective solutions

Author

Abdelkrim, Hmadcha, Hmadcha, Abdelkrim, Juan, Domínguez-Bendala, Domínguez-Bendala, Juan, Jane, Wakeman, Wakeman, Jane, Mohamed, Arredouani, Arredouani, Mohamed, Bernat, Soria, Soria, Bernat, [Hmadcha,A, Soria,B] Department of Cell Therapy and Regenerative Medicine, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Sevilla, Spain. [Domínguez-Bendala,J] Pancreatic Development & Stem Cell Laboratory, Diabetes Research Institute, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA. [Wakeman,J] North West Cancer Research Fund Institute, School of Biological Sciences, University of Wales Bangor, Memorial Building, Gwynedd, UK. [Mohamed,A] Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA, and This work was supported by the Consejería de Salud (Junta de Andalucía) and Fundación Progreso y Salud, the Spanish Ministry of Health, Red TerCel, North West Cancer Research Fund and Diabetes Research Institute Foundation

Subjects
Graft Rejection, Immune rejection, Phenomena and Processes::Immune System Phenomena::Immune System Processes::Transplantation Immunology::Histocompatibility [Medical Subject Headings], Reviews, Stem cells, Biology, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Immune system, Histocompatibilidad, Immune Tolerance, Organisms::Eukaryota::Animals [Medical Subject Headings], Animals, Humans, Células Madre, Cell therapies, Graft rejection, Phenomena and Processes::Immune System Phenomena::Immune System Processes::Immunomodulation::Immune Tolerance [Medical Subject Headings], Anatomy::Hemic and Immune Systems::Immune System [Medical Subject Headings], Cell Biology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Cell Transplantation::Stem Cell Transplantation [Medical Subject Headings], Anatomy::Cells::Stem Cells [Medical Subject Headings], Immune System, Histocompatibility, Immunology, Tratamiento Basado en Trasplante de Células y Tejidos, Molecular Medicine, Engineering ethics, Phenomena and Processes::Immune System Phenomena::Immune System Processes::Transplantation Immunology::Host vs Graft Reaction::Graft Rejection [Medical Subject Headings], Stem cell, Stem Cell Transplantation
Abstract

Stem cells have fascinated the scientific and clinical communities for over a century. Despite the controversy that surrounds this field, it is clear that stem cells have the potential to revolutionize medicine. However, a number of significant hurdles still stand in the way of the realization of this potential. Chiefly among these are safety concerns, differentiation efficiency and overcoming immune rejection. Here we review current progress made in this field to optimize the safe use of stem cells with particular emphasis on prospective interventions to deal with challenges generated by immune rejection. © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.

Published
2009

30. NAD+ protects against EAE by regulating CD4+ T-cell differentiation

Author

Tullius, Stefan G., primary, Biefer, Hector Rodriguez Cetina, additional, Li, Suyan, additional, Trachtenberg, Alexander J., additional, Edtinger, Karoline, additional, Quante, Markus, additional, Krenzien, Felix, additional, Uehara, Hirofumi, additional, Yang, Xiaoyong, additional, Kissick, Haydn T., additional, Kuo, Winston P., additional, Ghiran, Ionita, additional, de la Fuente, Miguel A., additional, Arredouani, Mohamed S., additional, Camacho, Virginia, additional, Tigges, John C., additional, Toxavidis, Vasilis, additional, El Fatimy, Rachid, additional, Smith, Brian D., additional, Vasudevan, Anju, additional, and ElKhal, Abdallah, additional

Published
2014
Full Text
View/download PDF

36. Targeting Tim-1 to Circumvent Immune Tolerance in Prostate Cancer

Author

BETH ISRAEL DEACONESS MEDICAL CENTER BOSTON MA, Arredouani, Mohamed S, BETH ISRAEL DEACONESS MEDICAL CENTER BOSTON MA, and Arredouani, Mohamed S

Abstract

Early-stage clinical testing raises the possibility that combinatorial approaches that augment tumor antigen-specific immune responses may accomplish significant tumor destruction without the induction of serious autoimmune disease. Accordingly, a rational and combinatorial manipulation of immune evasion pathways and their targets should aid in the development of safer and more effective vaccine strategies and immunotherapies for all stages of prostate cancer. In prostate cancer, a plausible combination that could be targeted towards patients who undergo androgen ablation, a therapeutic modality that is also known to enhance immune responses to prostate TAA, would include a vaccine in conjunction with biologic agents that are known to simultaneously augment antigen presentation by DCs and inhibit immunosuppressive cells such as regulatory T cells (Treg) or prolong the survival and enhance the vigor of tumor-specific lymphocytes. An example of such agents is the agonist antibody that targets TIM-1, a receptor expressed on lymphocytes and dendritic cells that enhances cytotoxic lymphocyte responses to tumor-associated antigens when used in combination with a vaccine. Here we explore the combination of androgen ablation and anti-TIM1 targeting as a strategy to ameliorate cancer-specific vaccine outcome in a mouse model of prostate cancer., The original document contains color images.

Published
2012

37. Targeting Tim-1 to Circumvent Immune Tolerance in Prostate Cancer

Author

BETH ISRAEL DEACONESS MEDICAL CENTER BOSTON MA, Arredouani, Mohamed S., BETH ISRAEL DEACONESS MEDICAL CENTER BOSTON MA, and Arredouani, Mohamed S.

Abstract

We have previously shown that manipulating lymphocytes through Tim1 receptor, a membrane protein that regulates the vigor and differentiation of T cells, using an agonist monoclonal antibody, enhances cytotoxic lymphocyte (CTL) responses to a model prostate tumor-associated antigen (SV40 T antigen) in tumor-free and tumor-bearing mice. This provided a tool to break immune tolerance to prostate tumor antigens in prostate cancer. We now demonstrate, using Tim1 deficient mice, that the effect of the antibody is mediated through Tim-1. We additionally demonstrate that its effect is maintained in humanized HLAA2.1 transgenic mice when these mice are immunized with peptides derived from the prostate tumor antigens ERG and SIM2. A similar effect was obtained in HLA-A2.1/ERG and HLA-A2.1/ERG/TRAMP. Our findings provide evidence that manipulating Tim1 with an agonist antibody at time of vaccination strengthens cytotoxic responses to mouse and human prostate tumorassociated antigens in healthy and prostate tumor-bearing mice. This represents a major step towards preclinical testing of this strategy against prostate tumor growth and progression and its translation into therapy for prostate cancer in humans., The original document contains color images.

Published
2011

38. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice

Author

Department of Urology & Department of Microbiology and Immunology, School of Medicine, University of Michigan, Ann Arbor, Michigan, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, Merck Research Laboratories, West Point, Pennsylvania, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts ; 330 Brookline Ave., Rabb 440, Boston, MA 02215., Arredouani, Mohamed S., Tseng-Rogenski, Stephanie S., Hollenbeck, Brent K., Escara-Wilke, June, Leander, Karen R., Defeo-Jones, Deborah, Hwang, Clara, Sanda, Martin G., Department of Urology & Department of Microbiology and Immunology, School of Medicine, University of Michigan, Ann Arbor, Michigan, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, Merck Research Laboratories, West Point, Pennsylvania, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts ; 330 Brookline Ave., Rabb 440, Boston, MA 02215., Arredouani, Mohamed S., Tseng-Rogenski, Stephanie S., Hollenbeck, Brent K., Escara-Wilke, June, Leander, Karen R., Defeo-Jones, Deborah, Hwang, Clara, and Sanda, Martin G.

Abstract

BACKGROUND In recent years, there has been an increasing interest in targeting human prostate tumor-associated antigens (TAAs) for prostate cancer immunotherapy as an alternative to other therapeutic modalities. However, immunologic tolerance to TAA poses a significant obstacle to effective, TAA-targeted immunotherapy. We sought to investigate whether androgen deprivation would result in circumventing immune tolerance to prostate TAA by impacting CD8 cell responses. METHODS To this end, we generated a transgenic mouse that expresses the human prostate-specific antigen (PSA) specifically in the prostate, and crossed it to the HLA-A2.1 transgenic mouse to evaluate how androgen deprivation affects human HLA A2.1-restricted T cell responses following immunization of PSA-expressing mice by vaccinia-PSA (PROSTVAC). RESULTS Our PSA transgenic mouse showed restricted expression of PSA in the prostate and detectable circulating PSA levels. Additionally, PSA expression was androgen-dependent with reduced PSA expression in the prostate within 1 week of castration, and undetectable PSA by day 42 after castration as evaluated by ELISA. Castration of the PSA/A2.1 hybrid mouse prior to immunization with a PSA-expressing recombinant vaccinia virus resulted in a significant augmentation of PSA-specific cytotoxic lymphocytes. CONCLUSIONS This humanized hybrid mouse model provides a well-defined system to gain additional insight into the mechanisms of immune tolerance to PSA and to test novel strategies aiming at circumventing immune tolerance to PSA and other TAA for targeted prostate cancer immunotherapy. Prostate?? 2010 Wiley-Liss, Inc.

Published
2010

39. The immune boundaries for stem cell based therapies: Problems and prospective solutions

Author

Hmadcha, Abdelkrim, Domínguez-Bendala, Juan, Wakeman, Jane, Arredouani, Mohamed, Soria Escoms, Bernat, Hmadcha, Abdelkrim, Domínguez-Bendala, Juan, Wakeman, Jane, Arredouani, Mohamed, and Soria Escoms, Bernat

Abstract

Stem cells have fascinated the scientific and clinical communities for over a century. Despite the controversy that surrounds this field, it is clear that stem cells have the potential to revolutionize medicine. However, a number of significant hurdles still stand in the way of the realization of this potential. Chiefly among these are safety concerns, differentiation efficiency and overcoming immune rejection. Here we review current progress made in this field to optimize the safe use of stem cells with particular emphasis on prospective interventions to deal with challenges generated by immune rejection. © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.

Published
2009

42. Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer

Author

Arredouani, Mohamed S., primary, Lu, Bin, additional, Bhasin, Manoj, additional, Eljanne, Miriam, additional, Yue, Wen, additional, Mosquera, Juan-Miguel, additional, Bubley, Glenn J., additional, Li, Vivian, additional, Rubin, Mark A., additional, Libermann, Towia A., additional, and Sanda, Martin G., additional

Published
2009
Full Text
View/download PDF

43. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy

Author

Haram, Kerstyn M., primary, Peltier, Heidi J., additional, Lu, Bin, additional, Bhasin, Manoj, additional, Otu, Hasan H., additional, Choy, Bob, additional, Regan, Meredith, additional, Libermann, Towia A., additional, Latham, Gary J., additional, Sanda, Martin G., additional, and Arredouani, Mohamed S., additional

Published
2008
Full Text
View/download PDF

49. MARCO Is the Major Binding Receptor for Unopsonized Particles and Bacteria on Human Alveolar Macrophages

Author

Arredouani, Mohamed S., primary, Palecanda, Aiyappa, additional, Koziel, Henry, additional, Huang, Yuh-Ching, additional, Imrich, Amy, additional, Sulahian, Timothy H., additional, Ning, Yao Yu, additional, Yang, Zhiping, additional, Pikkarainen, Timo, additional, Sankala, Marko, additional, Vargas, Sara O., additional, Takeya, Motohiro, additional, Tryggvason, Karl, additional, and Kobzik, Lester, additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results